New topical tranexamic acid derivative for the improvement of hyperpigmentation and inflammation in the sun‐damaged skin
- 25 June 2020
- journal article
- research article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (2) , 561-565
Abstract
Background: Skin‐lightening products are used worldwide to treat persistent pigmentation disorders that impact our quality of life and self‐confidence. However, consumers of cosmetic and over‐the‐counter skin lighteners struggle to find products that perform to their expectations. New, safe, and effective bioactives are needed to fill this gap.Objective: To investigate the safety and skin‐lightening performance of a new topical tranexamic acid derivative, that is, cetyl tranexamate mesylate.Methods: The test material was a facial serum containing 2.0% (w/w) of the new bioactive. Safety was evaluated by a modified Human Repeat Insult Patch Test with 54 subjects of either sex. Performance was objectively assessed based on the improvement of melanin and erythema indexes through time, and also subjectively by photographs and self‐perception questionnaires. Thirty‐five female subjects applied the serum twice a day for 8 weeks.Results: No questionable adverse reactions were observed. Melanin and erythema indexes improved significantly and continuously from the baseline to the end of the study (−16.9% and −34.3%, respectively). Photographs further support instrumental data. On average, after 2 weeks, the subjects already noticed an improvement in skin tone (79.3%), a reduction in dark spots (78.6%), and an improvement in facial redness (77.1%).Conclusion: A topical serum containing cetyl tranexamate mesylate was well‐tolerated and successfully improved the overall facial skin tone, as well as the appearance of dark spots and redness.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy and possible mechanisms of topical tranexamic acid in melasmaClinical and Experimental Dermatology, 2016
- Spectrometric analysis of mercury content in 549 skin-lightening products: Is mercury toxicity a hidden global health hazard?Journal of the American Academy of Dermatology, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double‐blind, vehicle‐controlled trialSkin Research and Technology, 2013
- Physical measurement and evaluation of skin color changes under normal condition and post‐ultraviolet radiation: a comparison study of Chromameter CM 2500d and Maxmeter MX18Skin Research and Technology, 2011
- Membranous nephropathy after use of UK-manufactured skin creams containing mercuryQJM: An International Journal of Medicine, 2010
- Mechanism of the Inhibitory Effect of Tranexamic Acid on Melanogenesis in Cultured Human Melanocytes in the Presence of Keratinocyte-conditioned MediumJournal of Health Science, 2007
- Mercury “bleaching” creamsJournal of the American Academy of Dermatology, 2005
- trans-4-(Aminomethyl)cyclohexane Carboxylic Acid (T-AMCHA), an Anti-Fibrinolytic Agent, Accelerates Barrier Recovery and Prevents the Epidermal Hyperplasia Induced by Epidermal Injury in Hairless Mice and HumansJournal of Investigative Dermatology, 1997
- The development of allergic contact dermatitis in females during the comparison of two predictive patch testsContact Dermatitis, 1977